Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high ...
Novartis announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 ( …